| Literature DB >> 28813021 |
Myung-Suk Lee1, Christine Youn2, Jeong Hyun Kim3, Byoung Jun Park4, Jongchan Ahn5, Sungyoul Hong6, Young-Deug Kim7, Young Kee Shin8,9, Sang Gyu Park10,11.
Abstract
The multipotency and anti-inflammatory effects of mesenchymal stem cells (MSCs) make them attractive for cell therapy in regenerative medicine. A large number of MSCs is required for efficient therapy owing to the low homing efficiency of MSCs to target sites. Furthermore, owing to limitations in obtaining sufficient amounts of MSCs, in vitro expansion of MSCs that preserves their differentiation and proliferative potential is essential. The animal factor included in culture media also limits clinical application. In this study, adipose-derived MSCs showed a significantly higher proliferation rate in STK2, a chemically-defined medium, than in DMEM/FBS. The expression of MSC surface markers was increased in the culture using STK2 compared to that using DMEM/FBS. Tri-lineage differentiation analyses showed that MSCs cultured in STK2 were superior to those cultured in DMEM/FBS. In addition, MSCs cultured in STK2 showed a reduced senescence rate, small and homogenous cell size, and were more genetically stable compared to those cultured in DMEM/FBS. Furthermore, secretome analysis showed that the expression of factors related to proliferation/migration, anti-inflammation, and differentiation were increased in STK2 culture medium compared to DMEM/FBS. Taken together, these results suggest that culture using STK2 medium offers many advantages through which it is possible to obtain safer, superior, and larger numbers of MSCs.Entities:
Keywords: chemically-defined medium; differentiation; mesenchymal stem cell; multipotency; proliferation; secretome
Mesh:
Substances:
Year: 2017 PMID: 28813021 PMCID: PMC5578168 DOI: 10.3390/ijms18081779
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Comparison of cell growth, population doubling time (PDT), and viability of ASCs cultured in DMEM/FBS and STK2. (A–C) ASCs (3 × 104 cells) at P2 were seeded onto 6 well-plates. Cell numbers and viability were evaluated as described in the Methods section (n = 4). PDT was calculated by the following formula: PDT = (T, culture time; q1, initial number of cells; q2, final number of cells) (n = 4). The values are means ± SD values. * p < 0.01.
Figure 2Analysis of ASC marker expression. (A) ASCs were cultured in DMEM/FBS or STK2, and stained with anti-CD29-PE, anti-CD44-PE, anti-CD73-PE, anti-CD90-PE, and anti-CD105-PE antibodies as positive markers, and anti-HLA-DR-FITC, -CD34-FITC, and -CD45-PE antibodies as negative markers. A representative image from three independent experiments is shown; (B) Total RNAs were isolated and qRT-PCR was performed to analyze the expression of CD markers as described in the Methods section. Data represent the mean ± SEM as an average of three independent experiments. * and ** vs. corresponding passage DMEM/FBS. * p < 0.01; ** p < 0.05.
Stain Index (SI) values of FACS analysis for detection of positive and negative MSC biomarker.
| Antibody | Passage | DMEM/FBS | STK2 |
|---|---|---|---|
| CD29 | P3 | 30.5 ± 5.1 | 57.0 ± 13.7 |
| P9 | 19.8 ± 7.4 | 48.4 ± 15.6 | |
| CD44 | P3 | 26.6 ± 7.4 | 39.9 ± 5.42 |
| P9 | 16.6 ± 3.7 | 37.5 ± 0.88 | |
| CD73 | P3 | 27.7 ± 5.5 | 41.5 ± 6.31 |
| P9 | 32.5 ± 6.5 | 43.5 ± 7.35 | |
| CD90 | P3 | 31.8 ± 6.1 | 38.3 ± 2.91 |
| P9 | 28.9 ± 5.3 | 46.3 ± 11.8 | |
| CD105 | P3 | 32.7 ± 15.4 | 6.51 ± 5.39 |
| P9 | 22.3 ± 11.9 | 8.04 ± 0.46 | |
| CD34 | P3 | 0.09 ± 0.09 | 0.19 ± 0.03 |
| P9 | 0.26 ± 0.11 | 0.14 ± 0.17 | |
| CD45 | P3 | 0.05 ± 0.01 | 0.08 ± 0.09 |
| P9 | 0.01 ± 0.02 | 0.13 ± 0.06 | |
| HLA-DR | P3 | −0.03 ± 0.01 | −0.01 ± 0.01 |
| P9 | −0.06 ± 0.09 | −0.04 ± 0.02 |
n = 3; mean ± SD.
Figure 3Comparison of trilineage differentiation capability of ASCs cultured in DMEM/FBS and STK2. (A) Differentiation into adipocytes, chondrocytes, and osteocytes was induced and stained as described in the Methods section. A representative image from three independent experiments is shown; (B) The staining intensity was quantitated and evaluated by ImageJ, and expressed as arbitrary intensity; (C) The mRNA expression levels of PPARγ (adipogenic marker), osteocalcin (osteogenic marker), and aggrecan (chondrogenic marker) were quantitated using qRT-PCR and presented as relative expression (n = 3). Data represent the mean ± SEM as an average of three independent experiments. * vs. corresponding passage DMEM/FBS. * p < 0.05.
Figure 4Comparison of senescence of ASCs cultured in DMEM/FBS and STK2. Cells at each passage were seeded and cultured for 24 h, then β-galactosidase was stained as described in the Methods section. (A) A representative image from three independent experiments is shown. Red * indicates β-galactosidase positive cell; (B) β-galactosidase-positive cells were counted and presented as a percentage. Data are represented as the mean ± SEM of the average of at least three independent experiments. * vs. DMEM/FBS. * p < 0.05.
Figure 5Comparison of cell size of ASCs cultured in DMEM/FBS and STK2. (A) Images were captured at the indicated passage using an IncuCyte ZOOM Live-Cell Analysis System at 100× magnification; (B) Adherent cell size was measured by analyzing phase-contrast images with ImageJ. Analyzed adherent cell sizes were compared by box-and-whisker plot. Data are represented as the mean ± SD of the average of at least three independent experiments. * and ** vs. DMEM/FBS. * p < 0.001; ** p < 0.0001.
Figure 6FACS analysis of ASCs cultured in DMEM/FBS and STK2. (A) Cellular homogeneity of ASCs was analyzed by FACS; (B) SSC-H distribution; and (C) average median values of SSC-H were compared using each indicated passage of ASCs cultured in DMEM/FBS and STK2; (D) Values over 300 in SSC-H were grouped as the high SSC (HSSC) population and values below 300 in SSC-H were grouped as the low SSC (LSSC) population. The change of each population is presented as a bar graph (n = 3).
Figure 7Analysis of genetic stability of ASCs cultured in DMEM/FBS and STK2. To examine the genetic stability of ASCs, cells were cultured in the presence or absence of mitomycin C (mit-C), and were subjected to CBMN assay as described in the Methods section. Mit-C was used as the positive control. (A) Binucleated cells were analyzed for the presence of micronuclei (MN), nucleoplasmic bridges (NPB), and nuclear buds (NBUD). Images were captured at 400× (scale bar, 10 μm); (B) Each frequency was evaluated and presented as a bar graph (n = 4). Data represent the mean ± SD of the average of at least three independent experiments. * vs. DMEM/FBS (P9). * p < 0.001.
Figure 8Secretome analysis of ASCs cultured in DMEM/FBS and STK2. (A) Supernatant of ASCs cultured in DMEM/FBS or STK2 at the indicated passage was analyzed using the human cytokine proteome array; (B and C) The relative intensity of each dot corresponding to a different factor was normalized by the intensity of the control. The factors with noticeably different relative detection levels between DMEM/FBS and STK2 groups are presented as bar graphs (n = 3).
Up- or down-regulated factors produced by ASCs cultured in STK2.
| Name | Function | |
|---|---|---|
| Up | Adiponectin | regulate glucose levels, fatty acid breakdown, adipocyte differentiation |
| Angiogenin | induce angiogenesis | |
| Cystatin C | induce proliferation of neural stem cell | |
| DKK_1 | inhibit WNT signaling pathway | |
| EMMPRIN | induce matrix metalloproteinase synthesis | |
| CD105 | mediate TGFβ signal | |
| FGF-19 | regulate cell proliferation, glucose and bile acid metabolism | |
| G-CSF | induce mesenchymal cell mobilization | |
| GDF-15 | regulate inflammatory and apoptotic pathways in injured tissues | |
| GM-CSF | promote proliferation of human fetal and adult microglia | |
| M-CSF | regulate the survival, proliferation and differentiation of hematopoietic precursor cells | |
| HGF | promote progenitor cell mobilization, induce angiogenesis and cell proliferation, inhibit immune cell proliferation | |
| CD54 | induce MSC-mediated immunosuppression | |
| IGFBP-2 | promote cell mobility and osteoblast differentiation | |
| IL-1ra | inhibit the pro-inflammatory effect of IL-1β | |
| Lipocalin-2 | protect MSC against unfavorable microenvironments and decrease MSC senescence | |
| CCL-7/MCP-3 | induce MSC migration and recruit MSC to site of injured tissue | |
| MIF | Induce MSC migration and promote cell proliferation of neural stem/progenitor cell | |
| CCL3 | induce MSC migration and recruit MSC to site of injured tissue | |
| CCL-20 | inhibit T cell activation and proliferation and induce MSC migration | |
| PDGF-AA | induce MSC migration and promote osteogenic differentiation | |
| MMP-9 | ECM remodeling and cell migration | |
| TSF-14 | inhibit atherosclerosis and protect cardiac function | |
| CXCL4 | protect MSC from acute radiation injury and maintain HSC stemness | |
| TFF3 | decrease IL-6 and IL-8 | |
| Thrombospondin-1 | induce MSC differentiation | |
| uPAR | inhibit tumor growth and induce chemotaxis of CD34+ hematopoietic stem cell | |
| Down | FGF-7 | reduce IL-1β and TNFα, and increase IL-10 |
| IGFBP-3 | induce cellular senescence | |
| IL-11 | induce inflammation to cancer progression and function as tumor promoting cytokine |
Primer sequences used for qRT-PCR.
| Primers | Sequences |
|---|---|
| CD29 | F, 5′-cgatgccatcatgcaagt-3′ |
| R, 5′-acaccagcagccgtgtaac-3′ | |
| CD44 | F, 5′-tgcctttgatggaccaatta-3′ |
| R, 5′-ggggtgtacagtagaaaagg-3′ | |
| CD73 | F, 5′-ccagtccactggagagttcc-3′ |
| R, 5′-cgacacttggtgcaaagaac-3′ | |
| CD90 | F, 5′-cagaacgtcacagtgctcaga-3′ |
| R, 5′-gaggagggagagggagagc-3′ | |
| CD105 | F, 5′-acgctccctctggctgtt-3′ |
| R, 5′-gctgaaggtcacaatggactg-3′ | |
| PPARγ | F, 5′-tcgctgatgcactgcctatg-3′ |
| R, 5′-gagaggtccacagagctga-3′ | |
| Aggrecan | F, 5′-gtggagccgtgtttccaag-3′ |
| R, 5′-agatgctgttgactcgaacct-3′ | |
| Osteocalcin | F, 5′-cgctaccttggagcttcagt-3′ |
| R, 5′-gtttggctttagggcagcac-3′ | |
| GAPDH | F, 5′-accccagcaaggacactgagcaag-3′ |
| R, 5′-ggctccctaggcccctcctgttatt-3′ |